Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
47 results about "Aneurysm dissecting" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dissecting aneurysm: An aneurysm in which the wall of an artery rips (dissects) longitudinally. This occurs because bleeding into the weakened wall splits the wall. Dissecting aneurysms tend to affect the thoracic aorta.
Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating
InactiveUS20070293937A1Preventing further weakeningPreventing dilationPeptide/protein ingredientsSurgeryAortic dissectionCathepsin
An endoluminal medical device comprises a drug release system that releases a cathepsin inhibitor at a predetermined location within a lumen of a patient. The endoluminal devices and methods of treatment of disease can treat illnesses such as aneurysms and aortic dissections.
Owner:COOK INC +1
Stabilization of aortic iliac neck diameter by use of radio frequency
A radio frequency probe is positioned in a body lumen, and the body lumen is heated, using the radio frequency probe, to stabilize the body lumen for insertion of a stent graft or stent. Specifically, the heating shrinks a diameter the body lumen. In one example, blood is allowed to flow through the body lumen during the heating, and in another example, blood flow is blocked through the body lumen during the heating. Another method inserts a metallic mesh in an aneurysmal sac of an aortic aneurysm and expanding the metallic mesh to contact a wall of the aneurysmal sac. The metallic mesh is used to electro-coagulate blood from a Type II endoleak.
Owner:MEDTRONIC VASCULAR INC
Method for forming aortic stent graft
InactiveCN106491241AEfficient preparationMade preciselyStentsAdditive manufacturing apparatusAorta partDip-coating
The invention discloses a method for forming an aortic stent graft. The method comprises the following steps: acquiring an image of aorta, and extracting a three-dimensional (3D) model of the aorta according to the image; extracting diameter characteristics of the aorta in the axial direction of the aorta of the 3D model; reconstructing an aortic vascular model according to the extracted diameter characteristics; 3D-printing a water-soluble vascular inner core according to the aortic vascular model; dip-coating a polymer film on a surface of the water-soluble vascular inner core; spirally weaving a metal mesh outside the treated water-soluble vascular inner core as a metal stent; bonding the polymer film and the metal stent, and then removing the water-soluble vascular inner core to obtain the aortic stent graft. The method provided by the invention can efficiently and accurately manufacture a vascular stent graft according to the actual size of a thoracic descending aorta of a patient based on a 3D printing technology, can effectively solve a detect that an existing equal-diameter vascular stent does not match a true vascular size of the patient, provides an effective medical means for treatment of acute vascular aneurysm, and has important clinical value.
Owner:TSINGHUA UNIV +1
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
ActiveUS20180273487A1Lower Level RequirementsShorten the lengthOrganic chemistryPharmaceutical delivery mechanismMorpholineResistance mutation
This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
Owner:UNIV OF TENNESSEE RES FOUND
Curved stent graft assembly
A stent graft assembly comprises a graft of flexible material supported by a stent frame that is configured to be deformable between an expanded state and a radially collapsed state. The graft of flexible material has the shape of a tube that is curved along a longitudinal axis of the tube when the graft is in an expanded, undeformed state. The stent graft assembly is deformable into a state in which the graft is deformed into the shape of a tube that is straight. The stent graft assembly may be designed for treatment of a thoracic aorta aneurysm.
Owner:ISIS INNOVATION LTD
Application of N6022 in prevention and treatment of aortic dissection and aortic aneurysm
ActiveCN111529524AInhibition of pathological expansionImprove the condition of the lesionOrganic active ingredientsCardiovascular disorderIntramural hematomaBlood vessel
The invention discloses application of N6022 in treatment of aortic dissection and aortic aneurysm, and relates to the field of cardiovascular diseases. In mouse models of aortic dissection and aorticaneurysm, dilation of aorta can be inhibited after intravenous injection of the N6022 into tail veins, thereby reducing incidence and mortality of aortic dissection and aortic aneurysm; and moreover,the N6022 is capable of reducing rupture of aortic aneurysm, inhibiting occurrence of hematoma in inner walls of lumen and excessive collagen deposition on vascular walls, maintaining integrity of elastic fibers in the vascular walls, and treating the aortic dissection and the aortic aneurysm. The application of the N6022 in the treatment of the aortic dissection and the aortic aneurysm opens upa new application field of the N6022, and provides a meaningful reference for the prevention and the treatment of the aortic dissection and the aortic aneurysm diseases as well as improvement of vascular lesions.
Owner:NANJING MEDICAL UNIV
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
Owner:UNIV OF TENNESSEE RES FOUND
Diagnosis and treatment related gene for abdominal aortic aneurysm
InactiveCN107177673AProvide survival rateMicrobiological testing/measurementAntineoplastic agentsSmooth muscleApoptosis
The invention discloses application of FAM210B in the preparation of diagnostic tools for abdominal aortic aneurysm. Experiments prove that FAM210B has expression differences in normal control tissues and abdominal aortic aneurysm tissues; therefore, it is reckoned that FAM210B is a molecular marker for diagnosing abdominal aortic aneurysm. Experiments via in-vitro cultured cells prove that by accelerating the expression of FAM210B, it is possible to inhibit the apoptosis of human aortic smooth muscle cells; therefore, it is reckoned that FAM210B is a drug target for treating abdominal aortic aneurysm. As a new molecular marker for diagnosing and treating abdominal aortic aneurysm, the molecular marker has a promising clinical application prospect.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Set of serum markers for detection of aortic aneurysm/aortic dissection and application thereof
The invention relates to a set of serum markers for detection of aortic aneurysm / aortic dissection and application thereof. The set of serum markers can be individually used for or arbitrarily combined for distinguishing aortic aneurysm / aortic dissection patients and normal people. The serum markers are protein factors, which include: LCN2: lipocalin, SAA: serum amyloid protein A.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
Owner:UNIV OF TENNESSEE RES FOUND
Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.
Owner:WARNER-LAMBERT CO
Aneurysm image analysis system and method based on double-flow boundary perception and equipment
ActiveCN112837218ASolve the mis-segmentation problemImprove accuracyImage enhancementImage analysisImaging analysisRadiology
The invention belongs to image analysis, particularly relates to an aneurysm image analysis system and method based on double-flow boundary perception and equipment, and aims to solve the problem that an aneurysm image cannot be accurately analyzed according to a developed image in an existing image analysis technology. The method comprises the steps of obtaining a DSA image of a region containing aortic aneurysm as a to-be-detected image, and generating an aortic aneurysm boundary feature image and an aortic aneurysm image mask through a trained double-flow boundary sensing network based on the to-be-detected image, and obtaining morphological information of the aortic aneurysm image based on the aortic aneurysm image mask and the aortic aneurysm boundary features in combination with the DSA image. The extracted features are input into the double-flow boundary sensing network, and the boundary features and the mask image are extracted and fused at the same time, so that the accuracy of the aneurysm image is improved, the problem that the boundary of the aneurysm image is fuzzy in the prior art is solved, and morphological analysis of the aneurysm can be carried out more accurately.
Owner:INST OF AUTOMATION CHINESE ACAD OF SCI +1
Bare stent capable of being compressed in axial direction
The invention relates to a bare stent capable of being compressed in an axial direction. The bare stent is used for an aorta and is formed by overlapping and interweaving at least two first wires and second wires with different diameters, in a natural release state, the bare stent has a metal coverage rate of at least 30%, and the diameter of the first wires is 20-150 micrometers, and the diameter of the second wires is 150-600 micrometers. When the bare stent is used for treating aortic aneurysm and / or aortic dissection lesion, low liquid permeability and strong radial supporting force are provided for a needed part in the aorta through the axial compressibility of the stent.
Owner:SHANGHAI FLOWDYNAMICS MEDICAL TECH CO LTD
Stent, stent set and stent delivery system
The invention relates to a stent, a stent set and a stent delivery system. The stent is used in the aorta and is characterized in that the stent is formed by weaving at least two kinds of first silk and second silk with different diameters, the stent is constructed to be at least partially compressible and extensible in the axial direction of the stent in a natural release state, the first silk has the diameter of 20-150 microns, and the second silk has the diameter of 150-800 microns. When the stent is used for treating aortic aneurysm and / or aortic dissection lesions, low liquid permeability and strong radial supporting force are provided for the required part in the aorta through the axial compressibility and extensibility of the stent, and the stent is easily assembled into the delivery system with the proper diameter through the axial extensibility of the stent. The invention further provides the stent set comprising the stent and the stent delivery system.
Owner:SHANGHAI FLOWDYNAMICS MEDICAL TECH CO LTD
Methods for Producing a Non Human Model for Aortic Aneurysm
InactiveUS20100260726A1Reduce the numberReduced activityBiocidePeptide/protein ingredientsDiseaseHuman animal
The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Application of R-ketorolac in prevention and treatment of aortic dissection and aortic aneurysm
ActiveCN113712960AInhibition of pathological expansionInhibition of hematomaOrganic active ingredientsAntineoplastic agentsIntramural hematomaKetorolac
The invention provides application of R-ketorolac in prevention and treatment of aortic dissection and aortic aneurysm. The R-ketorolac is orally taken to inhibit pathological expansion of aorta and reduce the occurrence rate and death rate of the aortic dissection and aortic aneurysm; and the R-ketorolac can inhibit the occurrence of vascular wall inflammatory reaction, reduce rupture of aortic aneurysm bodies, inhibit the occurrence of hematoma in the inner wall of a lumen, maintain the integrity of vascular wall elastic fibers and treat the aortic dissection and aortic aneurysm. The invention develops a new application field of the R-ketorolac, and provides a significant reference for preventing and treating aortic dissection and aortic aneurysm diseases and improving vascular lesion conditions.
Owner:NANJING MEDICAL UNIV
Effect of exosome in thoracic aortic dissection/aneurysm
PendingCN114099545AImprove survival rateCell dissociation methodsUnknown materialsPharmaceutical drugExosome
The invention relates to the field of biomedicine, in particular to an effect of an exosome in thoracic aortic dissection / aneurysm. The survival rate of a normal mouse group within 30 days is 100%, the survival rate of an aortic dissection / aneurysm group established by using a BAPN drug to induce mice begins to be reduced at the beginning of the third week, the total survival rate is maintained at 50% at the fourth week of an experimental period, and on the basis, the exosome group is injected, so that the survival rate of the mice is slightly reduced after the third week, and the survival rate of the mice is maintained at 50% at the beginning of the third week. When the experiment period is 4 weeks, the survival rate is maintained at 70%. According to the data, the occurrence of thoracic aortic dissection / aneurysm can be obviously delayed after the exosome is injected.
Owner:SUZHOU UNIV
Computed tomography aortic aneurysm auxiliary diagnosis method based on deep learning
ActiveCN113223704AEasy diagnosisEnhanced film readingImage enhancementImage analysisAorta aorticData set
The invention belongs to the technical field of aortic aneurysm auxiliary diagnosis, and particularly relates to a deep learning-based computed tomography aortic aneurysm auxiliary diagnosis method, which comprises the following steps of: 1, data acquisition: firstly, retrospectively collecting a plurality of common CT scans with aorta from a hospital area of a hospital; 2, data processing: dividing the data into three data sets: a training set, an internal test set and an external test set; and 3, establishing a model, constructing an auxiliary diagnosis tool by using an Attention-Unet convolutional neural network, evaluating the risk, detection sensitivity, specificity and accuracy of the aortic aneurysm in a test set by using the auxiliary diagnosis tool. The method is reasonable in design and has good diagnosis capability on aortic aneurysm; when the method is used in combination with radiologists, the film reading and decision-making capabilities of the radiologists can be remarkably enhanced, and the overall strength of imaging departments is improved. Therefore, the performance of the advanced technology proves that the non-invasive, cheap and convenient method has the potential of clinical tests.
Owner:JILIN UNIV
Stent Grafts And Methods Of Use For Treating Aneurysms
ActiveUS20190328557A1Low profileDiameter minimizationStentsBlood vesselsThoracoabdominal Aortic AneurysmsStent grafting
A stent graft includes a tubular aortic component that defines a lumen and a fenestration with a pocket at the fenestration. At least one proximal tunnel graft extends proximally within the lumen from the proximal opening of the pocket and is secured at a proximal end to the tubular component, and at least one distal tunnel graft extends distally within the lumen from the distal opening of the pocket and is secured at a distal end to the tubular aortic component. The stent graft can further include at least one branch stent graft, each of which extends through the fenestration and within at least one of the proximal tunnel graft or the distal tunnel graft. The stent graft can be implanted in a patient to thereby treat an aneurysm, such as a suprarenal or thoracoabdominal aortic aneurysm.
Owner:BOLTON MEDICAL INC
Bare stent compressible and stretchable in axial direction
The invention relates to a bare stent compressible and stretchable in the axial direction. The bare stent is used in the aorta and provided with at least two layers of woven meshes, and is characterized in that the bare stent is provided with a non-sparse-mesh area and a sparse-mesh area; the non-sparse-mesh area is formed by overlapping and interweaving at least two kinds of first wires and second wires with different diameters, the first wires have the diameter of 20-150 microns, and the second wires have the diameter of 150-600 microns; the sparse-mesh area is only composed of the second wires and is arranged at the position, with a branch artery, in the corresponding treatment position after the bare stent is released; and in the natural release state, except the sparse-mesh area, the bare stent has the metal coverage rate of at least 60%. The present invention relates to the bare stent for the treatment of aortic aneurysms and / or aortic dissection lesions, in particular type A aortic dissection, which is axially stretchable and radially compressible in a released state to obtain a delivery configuration of suitable dimensions for performing a procedure using a delivery catheter conventionally delivered through the femoral artery.
Owner:SHANGHAI FLOWDYNAMICS MEDICAL TECH CO LTD
Pharmaceutical application of hydrogen sulfide synthase CSE
InactiveCN112826927AReduced expression levelImproved endothelial damageCarbon-sulfur lyasesPeptide/protein ingredientsPharmaceutical drugHydrogen sulfide synthesis
The invention relates to pharmaceutical application of hydrogen sulfide synthase (CSE), in particular to application in preparation of drugs for treating aortic aneurysm and aortic dissection. The CSE adeno-associated virus improves the endothelial function and inhibits the onset of aortic aneurysm and aortic dissection. According to the invention, the effect of the hydrogen sulfide synthase CSE on endothelial injury caused by mechanical traction and prevention of aortic aneurysm and aortic dissection is defined. A new means is provided for treating the main aneurysm and the aortic dissection.
Owner:NANJING MEDICAL UNIV
Regulating the level of septin2 sulfhydryl nitrosylation modification for pharmaceutical use
The pharmaceutical use of regulating the level of thiol nitrosylation modification of Septin2 belongs to the field of molecular biology diagnosis of aortic aneurysm and aortic dissection. The present invention uses lentivirus infection into macrophages to down-regulate the mercapto nitroso at the Cys111 site of Septin2 protein Kylation modification can effectively inhibit the occurrence of aortic aneurysm and aortic dissection.
Owner:NANJING MEDICAL UNIV
Methods for producing a non human model for aortic aneurysm
InactiveUS8586822B2Extended half-lifeImprove stabilityBiocidePeptide/protein ingredientsDiseaseMechanical engineering
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Pharmaceutical application of lentivirus in regulating sulfydryl nitrosylation modification level of Septin2
The invention relates to a pharmaceutical application of a lentivirus in regulating the sulfydryl nitrosation modification level of Septin2, belonging to the field of molecular biology diagnosis of aortic aneurysm and aortic dissection. According to the invention, the occurrence of the aortic aneurysm and the aortic dissection can be effectively inhibited by infecting the lentivirus into macrophages to down-regulate the sulfydryl nitrosation modification of the Cys111 site of the Septin2 protein.
Owner:NANJING MEDICAL UNIV
Application of Crocetin in Prevention and Treatment of Thoracic Aortic Dissection/Aortic Aneurysm
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Use of tyrosine hydroxylase inhibitors for the treatment of aortic aneurysm
PendingUS20210283083A1Organic active ingredientsBlood disorderTyrosine Hydroxylase InhibitorTyrosine
The present invention relates to the use of a compound that can inhibit tyrosine hydroxylase, such as alpha-methyl-p-tyrosine (AMPT), for the prevention or treatment of aortic aneurysm, preferably of the abdominal aortic.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +1
Pharmaceutical application of hydrogen sulfide donor
InactiveCN112891368AIncreased hydrogen sulfide levelsImprove the level ofSulfur/selenium/tellurium active ingredientsAntineoplastic agentsInflammatory factorsSodium hydrosulfide
The invention provides pharmaceutical application of a hydrogen sulfide donor, particularly relates to application of hydrogen sulfide and a hydrogen sulfide donor in preparation of medicines for treating aortic aneurysm and aortic dissection, and particularly relates to application of sodium hydrosulfide, DATS, L-cysteine and analogues thereof, GYY4137, ADT-OH and analogues thereof, and Gem-dithiol and analogues thereof in preparation of medicines for treating aortic aneurysm and aortic dissection. According to the invention, through an integral animal model, the hydrogen sulfide and the hydrogen sulfide donor are determined to be capable of reducing the occurrence rate and death rate of aortic aneurysm and aortic dissection, increasing the content of hydrogen sulfide in circulating blood, inhibiting expression of inflammatory factors in the process of aortic aneurysm and aortic dissection, and improving loss of smooth muscle cells in the process of aortic aneurysm and aortic dissection. The hydrogen sulfide donor can be used as a treatment medicine for improving occurrence and development of aortic aneurysm and aortic dissection.
Owner:NANJING MEDICAL UNIV
Aneurysm image analysis system, method and device based on dual-flow boundary perception
ActiveCN112837218BSolve the mis-segmentation problemImprove accuracyImage enhancementImage analysisImaging analysisRadiology
Owner:INST OF AUTOMATION CHINESE ACAD OF SCI +1
A class of oral gsnor inhibitors and their pharmaceutical use
ActiveCN112574193BReduced ability to migratePromote recoveryOrganic active ingredientsOrganic chemistryDiseaseLimb ischemia
Owner:NANJING MEDICAL UNIV
Pharmaceutical composition for treating aortic aneurysm
PendingUS20220184058A1Improved non-rupture survival rateImprove survival rateMetabolism disorderCardiovascular disorderPharmaceutical drugQuinolizine
The present invention addresses the problem of providing a therapeutic agent for an abdominal aortic aneurysm, the therapeutic agent making drug therapy possible.The present invention provides a therapeutic agent for aortic aneurysm, the therapeutic agent having as active ingredients: (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these; and a statin.
Owner:KOWA CO LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com